Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:2085–2098. doi: 10.1056/NEJMoa065485
Drüeke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:2071–2084. doi: 10.1056/NEJMoa062276
Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:2019–2032. doi: 10.1056/NEJMoa0907845
Chertow GM, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 2021; 384:1589–1600. doi: 10.1056/NEJMoa2035938
Chen N, et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N Engl J Med 2019; 381:1001–1010. doi: 10.1056/NEJMoa1813599
Coyne DW, et al. Roxadustat for CKD-related anemia in non-dialysis patients. Kidney Int Rep 2020; 6:624–635. doi: 10.1016/j.ekir.2020.11.034
Fishbane S, et al. Roxadustat for treating anemia in patients with CKD not on dialysis: Results from a randomized phase 3 study. J Am Soc Nephrol 2021; 32:737–755. doi: 10.1681/ASN.2020081150
Provenzano R, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant 2021; 36:1717–1730. doi: 10.1093/ndt/gfab051
Eckardt KU, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med 2021; 384:1601–1612. doi: 10.1056/NEJMoa2025956